A Phase 2 interventional study of Codman 3000 constant flow pump catheter and Panitumumab in Colorectal Cancer, Liver Metastases and Colorectal Adenocarcinoma, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing floxuridine in Colorectal Neoplasms — 5 open to participants now, 6 under way, 3 of them phase 3. Floxuridine · Colorectal Neoplasms.
Among the 27 studies testing floxuridine in Colorectal Neoplasms, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2019, is one of 14 in phase 2, and was the 18th registered.
6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →5 of the 27 studies testing floxuridine in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
ECOG-ACRIN Cancer Research Group · Sites in United States
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Yuhong Li · Sites in China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Floxuridine: first FDA approval 1970 (FUDR). What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9
First in 1994; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 49 across the 25 interventional studies. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 27 have an industry lead sponsor. The 10 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
94 studies in Colorectal Neoplasms by National Cancer Institute (NCI): 20 open now, 35 under way, 1 of them phase 3. Of 54 finished, 21 (39%) have results posted.
Among the 94 studies in Colorectal Neoplasms by National Cancer Institute (NCI), this one is the 50th largest by enrollment of the 74 interventional ones that give a count, is one of 5 that started in 2019, is one of 43 in phase 2, and was the 59th registered.
National Cancer Institute (NCI)’s Colorectal Neoplasms studies by the year they started, since 1995.
1 of the studies testing floxuridine in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01815359Memorial Sloan Kettering Cancer CenterICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing floxuridine in Colorectal Neoplasms, from their registry updates:
Among National Cancer Institute (NCI)’s 94 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
Background:
Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective. A device that does this a pump that delivers drugs over 2 weeks at constant rate into the hepatic artery. The person's body temperature causes the drug to flow from the pump. Researchers want to see if this helps people with colorectal metastases to the liver.
Objective:
To study the effectiveness of a hepatic artery infusion pump at treating colorectal metastases to the liver.
Eligibility:
Adults at least 18 years old with colorectal metastases to the liver
Design:
Participants will be screened with:
Medical history
Physical exam
Heart, blood, and urine tests
Scans
Participants will stay in the hospital a few days. A small plastic tube (catheter) will be inserted in an artery into the liver. The catheter will be attached to the pump. That will lie under the skin on the abdomen. It will be small and participants will be able to feel it.
Participants will get treatment in 28-day cycles.
Every Day 1, they will have physical exam, symptom review, and blood tests.
Every 2 weeks, they will come to the clinic to get chemotherapy by a catheter or port.
Every 12 weeks, they will have a scan.
Tissue samples may be taken during the study.
When they finish the drug, participants may have the pump removed. They will repeat the Day 1 tests. They will be called every 6 months to see how they are doing.
Background:
Objective:
Eligibility:
Design:
- Single arm, Phase II study of HAIP chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have adequate organ and marrow function as defined below:
EXCLUSION CRITERIA:
Note: The exception to this exclusion is patients with fewer than five lung lesions greater than 1 cm that have not increased in size by more than 10% over a 4-month period of time, and are amenable to resection should subsequent problematic growth occur. Lesions less than 1 cm are indeterminant as far as etiology is concerned and will be ignored. Patients with liver metastases and oligometastatic lung lesions (we define oligometastatic as less than 5 amenable to thoracoscopic removal) are still likely to benefit from liver directed therapy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HAIP chemotherapy + Systemic chemotherapy
Device: Codman 3000 constant flow pump catheter · Drug: Panitumumab · Drug: FUDR-Dex · Drug: Oxaliplatin · Drug: 5FU · Drug: Irinotecan · Procedure: HAIP installation · Drug: cetuximab · Device: Medtronic SynchroMed II Pump · Drug: Floxuridine · Drug: Dexamethasone · Diagnostic Test: EKG · Diagnostic Test: CT C/A/P · Diagnostic Test: CT Angiogram (abdomen) · Procedure: Tumor and normal liver biopsy · Drug: Leucovorin
Implanted Medtronic SynchroMed II Pump with codman 3000 Constant Flow Pump Catheter
6 mg/kg, intravenous (IV)
Also known as: Vectibix
Hepatic Artery Infusion Pump (HAIP) will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate), Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
Also known as: Floxuridine and Dexamethasone
85 mg/m\^2, intravenous (IV)
Also known as: Eloxatin
2000 mg/m\^2, intravenous (IV) 46-hour infusion of 5-Fluorouracil + 400 mg/m\^2, IV of Leucovorin
Also known as: 5-Fluorouracil
150 mg/m\^2, intravenous (IV)
Also known as: Camptosar, Onivyde
Hepatic Artery Infusion (HAI) pump installation
Also known as: Hepatic Artery Infusion Pump (HAIP) installation
500 mg/m\^2, intravenous (IV)
Also known as: Erbitux
Implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
Floxuridine 0.12 mg/kg X pump volume X pump flow rate
Also known as: 5-fluorodeoxyuridine
1 mg/day X pump volume (30) X pump flow rate
Also known as: Decadron
Screening and baseline.
Also known as: Electrocardiogram
Screening, baseline and Cycle 1. One cycle is 28 (+/- 2 days).
Also known as: Computed tomography chest, abdomen, pelvis
Screening
Also known as: Computed tomography angiogram (abdomen)
For research: During surgery to install pump, time of progression per principal investigator discretion if safe, and end of treatment.
Also known as: Tumor and normal liver bx
400 mg/m\^2, intravenous (IV), (Day15, Day1)
Also known as: folinic acid
Response Rate (RR) Reported With an 80% Confidence Interval
Response rate is defined as the number of participants who experience a partial response (PR) or complete response (CR) using the study treatment was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) and reported with an 80% confidence interval. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
Time frame: 6 months
Response Rate (RR) Reported With a 95% Confidence Interval
Response rate is defined as the percentage of participants who experience a partial response (PR) or complete response (CR) using the study treatment determined by dividing the number of responders by the total evaluable participants. RR was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and reported with an 95% confidence interval. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
Time frame: 6 months
Number of Grade 1, 2, 3, 4, and/or 5 Serious and/or Non-serious Adverse Events Reported With Type and Frequency
Safety was determined by grade 1, 2, 3, 4, and/or 5 serious and/or non-serious adverse events with type and frequency assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
Time frame: 30 days
Overall Survival
OS is defined as the median amount of time a participant survives after therapy determined using the Kaplan Meier method. The 95% confidence intervals were obtained using the Brookmeyer-Crowley method via a log-log (complementary log-log) transformation. As pre-specified in the protocol Statistical Section 10.4.3 Analysis of the Secondary Efficacy Endpoints, Overall survival (OS) will be calculated "from the date the patient enrolled onto the trial." The Responsible Party's rationale for reporting a different time frame is "The RP's preference is to report from the date of pump insertion given the time variability from enrollment to surgery, which is a function of operating room (OR) availability, and nothing related to the study.
Time frame: Date of Hepatic Artery Infusion Pump (HAIP) insertion through death or study completion, up to 63.1 months
Intra-Hepatic Progression-free Survival (PFS)
Intrahepatic PFS is defined as the duration of time from date of operation to the date of first observation of progressive disease within the liver or death, whichever comes first. Progression was measured by the Response Evaluation Criteria in Solid Tumors and determined using the Kaplan Meier method. Progression is at least a 20% increase in the sum of the diameters of target lesions. The 95% confidence intervals were obtained using the Brookmeyer-Crowley method via a log-log (complementary log-log) transformation. As prespecified in the protocol Statistical Section 10.4.3 Intra-hepatic PFS will be calculated "from the date the patient enrolled onto the trial." The Responsible Party's (RP) rationale for reporting a different time frame is "The RP's preference is to report from the date of pump insertion given the time variability from enrollment to surgery, which is a function of operating room (OR) availability, and nothing related to the study.
Time frame: Date of hepatic artery infusion pump (HAIP) insertion through either the date of first hepatic progression or study completion, up to 63.1 months
Extra-hepatic Progression-free Survival (PFS)
Extra-hepatic PFS is defined as the duration of time from date of operation to the date of first observation of progressive disease outside of the liver or death, whichever comes first. Extra-hepatic PFS was determined using the KaplanMeier method\&reported with a 95% confidence interval. Progression was measured by the Response Evaluation Criteria in Solid Tumors. Progression is at least a 20% increase in the sum of the diameters of target lesions. The 95% confidence intervals were obtained using the Brookmeyer-Crowley method via a log-log(complementary log-log) transformation. As prespecified in the protocol Statistical Section 10.4.3Extra-hepatic PFS will be calculated "from the date the patient enrolled onto the trial." The Responsible Party's((RP) rationale for reporting a differently is "RP's preference is to report from the date of pump insertion given the time variability from enrollment to surgery,which is a function of operating room availability\¬hing related to the study.
Time frame: Date of hepatic artery infusion pump (HAIP) insertion through either the date of first extra-hepatic progression or study completion, up to 63.1 months
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Adverse Events were monitored/assessed from the time of operation through 30 days after the participant was taken off treatment, up to 27.7 months
| Milestone | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Started | 24 |
| Enrolled | 24 |
| Intraoperative screen failures | 2 |
| Completed ≥ 1 cycle of treatment | 22 |
| Autoimmune disease not comparable with nct05286814 | 1 |
| Lost to follow-up | 1 |
| Final cohort of treated participants | 20 |
| Completed | 20 |
| Not completed | 4 |
| Withdrew: Participants deemed ineligible after signing consent | 1 |
| Withdrew: Did not receive treatment. | 2 |
| Withdrew: Physician decision | 1 |
Response rate is defined as the number of participants who experience a partial response (PR) or complete response (CR) using the study treatment was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) and reported with an 80% confidence interval. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
| percentage of participants | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Partial Response | 25 (12.7 to 41.5) |
| Complete Response | 10 (2.7 to 24.5) |
Response rate is defined as the percentage of participants who experience a partial response (PR) or complete response (CR) using the study treatment determined by dividing the number of responders by the total evaluable participants. RR was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and reported with an 95% confidence interval. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.
| percentage of participants | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Partial Response | 25 (8.7 to 49.1) |
| Complete Response | 10 (1.2 to 31.7) |
Safety was determined by grade 1, 2, 3, 4, and/or 5 serious and/or non-serious adverse events with type and frequency assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event.
| adverse events | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|---|
| Abdominal distention: Non-serious | 0 | 1 | 0 | 0 | 0 |
| Abdominal distension: Serious | 0 | 1 | 0 | 0 | 0 |
| Abdominal pain: Non-Serious | 2 | 4 | 3 | 0 | 0 |
| Acidosis: Non-Serious | 1 | 0 | 2 | 0 | 0 |
| Activated Partial Thromboplastin Time Prolonged: Non-Serious | 1 | 3 | 0 | 0 | 0 |
| Alanine aminotransferase increased: Non-Serious | 1 | 25 | 22 | 6 | 0 |
| Alkaline aminotransferase increased: Non-Serious | 2 | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased: Non-Serious | 2 | 16 | 3 | 0 | 0 |
| Alopecia: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Anemia: Non-Serious | 0 | 41 | 28 | 0 | 0 |
| Anorexia: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Arthralgia: Non-Serious | 0 | 1 | 1 | 0 | 0 |
| Ascites: Non-Serious | 1 | 1 | 1 | 0 | 0 |
| Aspartate aminotransferase increased | 1 | 22 | 22 | 9 | 0 |
| Atelectasis: Non-Serious | 1 | 2 | 1 | 0 | 0 |
| Atrial fibrillation: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Back pain: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Belching: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Bloating: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Blood bilirubin increased: Non-Serious | 1 | 16 | 4 | 0 | 0 |
| Bile duct stenosis: Serious | 0 | 0 | 1 | 0 | 0 |
| Cardiac arrest: Serious | 0 | 0 | 0 | 1 | 0 |
| Chest pain: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Chylothorax: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Constipation: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| CPK increased: Non-Serious | 0 | 1 | 1 | 0 | 0 |
| Creatinine increased: Non-Serious | 0 | 2 | 0 | 0 | 0 |
| Device related infection: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Device related infection: Serious | 0 | 0 | 2 | 0 | 0 |
| Diarrhea: Non-Serious | 1 | 6 | 0 | 0 | 0 |
| Dry eye: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Duodenal perforation: Serious | 0 | 0 | 0 | 1 | 0 |
| Dyspnea: Non-Serious | 1 | 1 | 0 | 0 | 0 |
| Edema limbs: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Edema trunk: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Erectile dysfunction: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Fatigue: Non-Serious | 4 | 8 | 1 | 0 | 0 |
| Fever: Non-Serious | 0 | 3 | 0 | 0 | 0 |
| Fibrinogen decreased: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Flu-like symptoms: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Gastritis: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Generalized edema: Non-Serious | 1 | 0 | 1 | 0 | 0 |
| Heart failure: Non-Serious | 0 | 0 | 1 | 0 | 0 |
| Hematoma: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Hemorrhoidal hemorrhage: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Hyperhidrosis: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Hyperkalemia: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Hypertension: Non-Serious | 0 | 4 | 3 | 0 | 0 |
| Hypoalbuminemia: Non-Serious | 0 | 16 | 2 | 0 | 0 |
| Hypokalemia: Non-Serious | 0 | 0 | 5 | 0 | 0 |
| Hypotension: Non-Serious | 0 | 4 | 3 | 0 | 0 |
| Hypoxia: Non-Serious | 0 | 2 | 3 | 0 | 0 |
| Infections and infestations - Other, specify (Influenza A): Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Infusion-related reaction: Non-Serious | 0 | 2 | 0 | 0 | 0 |
| injury,poisoning and procedural complications,Other,specify (abdominal fluid collection):Non-Serious | 0 | 1 | 0 | 0 | 0 |
| INR increased: Non-Serious | 1 | 5 | 0 | 0 | 0 |
| Insomnia: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Intra-abdominal hemorrhage: Non-Serious | 0 | 0 | 1 | 0 | 0 |
| Lymphocyte count decreased: Non-Serious | 0 | 9 | 3 | 2 | 0 |
| Mania: Non-Serious | 0 | 0 | 1 | 0 | 0 |
| Mucositis oral: Non-Serious | 0 | 2 | 1 | 0 | 0 |
| Muscle weakness lower limb: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Nausea: Non-Serious | 2 | 2 | 0 | 0 | 0 |
| Neutrophil count decreased: Non-Serious | 0 | 6 | 2 | 1 | 0 |
| Non-cardiac chest pain: Non-Serious | 0 | 2 | 1 | 0 | 0 |
| Otitis media: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Pain: Non-Serious | 1 | 2 | 0 | 0 | 0 |
| Papulopustular rash: Non-Serious | 1 | 2 | 0 | 0 | 0 |
| Pericardial effusion | 0 | 0 | 0 | 0 | 0 |
| Peripheral sensory neuropathy | 0 | 2 | 0 | 0 | 0 |
| Platelet count decreased: Non-Serious | 0 | 6 | 3 | 0 | 0 |
| Pleural effusion: Non-Serious | 2 | 2 | 1 | 0 | 0 |
| Pleural effusion: Serious | 0 | 0 | 1 | 0 | 0 |
| Pleuritic pain: Non-Serious | 1 | 0 | 0 | 0 | 0 |
| Pneumothorax: Non-Serious | 0 | 0 | 1 | 0 | 0 |
| Premature menopause: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Pruritis: Non-Serious | 1 | 1 | 0 | 0 | 0 |
| Pulmonary edema: Serious | 0 | 0 | 1 | 0 | 0 |
| Rash acneiform: Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Rash maculopapular: Non-Serious | 2 | 2 | 0 | 0 | 0 |
| Renal and urinary disorders - Other, specify, (Oliguric renal failure): Non-Serious | 0 | 1 | 0 | 0 | 0 |
| Renal and urinary disorders - Other, specify, (Ureter injury) | 0 | 0 | 1 | 0 | 0 |
| Sepsis: Serious | 0 | 0 | 0 | 0 | 1 |
| Sinus tachycardia: Non-Serious | 0 | 4 | 0 | 0 | 0 |
| Skin ulceration: Non-Serious | 0 | 0 | 1 | 0 | 0 |
| Stroke: Serious | 0 | 0 | 0 | 0 | 1 |
| Syncope: Non-Serious | 0 | 0 | 1 | 0 | 0 |
| Thromboembolic event: Non-Serious | 0 | 0 | 1 | 0 | 0 |
| Thromboembolic event: Serious | 0 | 0 | 1 | 0 | 0 |
| Urinary retention: Non-Serious | 0 | 2 | 0 | 0 | 0 |
| Urinary tract infection: Non-Serious | 0 | 2 | 0 | 0 | 0 |
| Vascular disorders - Other, specify (Pseudoaneurysm of the GDA): Serious | 0 | 0 | 0 | 1 | 0 |
| Weight gain: Non-Serious | 1 | 1 | 0 | 0 | 0 |
| White blood cell decreased: Non-Serious | 0 | 7 | 3 | 0 | 0 |
| Wound dehiscence: Serious | 0 | 0 | 1 | 0 | 0 |
| Wound infection: Non-Serious | 0 | 0 | 2 | 0 | 0 |
OS is defined as the median amount of time a participant survives after therapy determined using the Kaplan Meier method. The 95% confidence intervals were obtained using the Brookmeyer-Crowley method via a log-log (complementary log-log) transformation. As pre-specified in the protocol Statistical Section 10.4.3 Analysis of the Secondary Efficacy Endpoints, Overall survival (OS) will be calculated "from the date the patient enrolled onto the trial." The Responsible Party's rationale for reporting a different time frame is "The RP's preference is to report from the date of pump insertion given the time variability from enrollment to surgery, which is a function of operating room (OR) availability, and nothing related to the study.
| Months | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Overall Survival | 17.9 (10.2 to 28.0) |
Intrahepatic PFS is defined as the duration of time from date of operation to the date of first observation of progressive disease within the liver or death, whichever comes first. Progression was measured by the Response Evaluation Criteria in Solid Tumors and determined using the Kaplan Meier method. Progression is at least a 20% increase in the sum of the diameters of target lesions. The 95% confidence intervals were obtained using the Brookmeyer-Crowley method via a log-log (complementary log-log) transformation. As prespecified in the protocol Statistical Section 10.4.3 Intra-hepatic PFS will be calculated "from the date the patient enrolled onto the trial." The Responsible Party's (RP) rationale for reporting a different time frame is "The RP's preference is to report from the date of pump insertion given the time variability from enrollment to surgery, which is a function of operating room (OR) availability, and nothing related to the study.
| Months | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Intra-Hepatic Progression-free Survival (PFS) | 10.8 (7.1 to 23.1) |
Extra-hepatic PFS is defined as the duration of time from date of operation to the date of first observation of progressive disease outside of the liver or death, whichever comes first. Extra-hepatic PFS was determined using the KaplanMeier method\&reported with a 95% confidence interval. Progression was measured by the Response Evaluation Criteria in Solid Tumors. Progression is at least a 20% increase in the sum of the diameters of target lesions. The 95% confidence intervals were obtained using the Brookmeyer-Crowley method via a log-log(complementary log-log) transformation. As prespecified in the protocol Statistical Section 10.4.3Extra-hepatic PFS will be calculated "from the date the patient enrolled onto the trial." The Responsible Party's((RP) rationale for reporting a differently is "RP's preference is to report from the date of pump insertion given the time variability from enrollment to surgery,which is a function of operating room availability\¬hing related to the study.
| percentage of participants | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Extra-hepatic Progression-free Survival (PFS) | 8.1 (5.9 to 13.1) |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
| Participants | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 24 |
Collected over All-Cause Mortality was monitored/assessed from the date of surgery (hepatic artery infusion pump insertion) through the completion date of the study, up to a maximum of 61.2 months. Adverse Events were monitored/assessed from the time of operation through 30 days after the participant was taken off treatment, up to 27.7 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo | 10/24 (41.7%) | 7/24 (29.2%) | 23/24 (95.8%) |
| Event | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Device related infectionInfections and infestations | 2/24 |
| Wound dehiscenceInjury, poisoning and procedural complications | 2/24 |
| Abdominal distensionGastrointestinal disorders | 1/24 |
| Bile duct stenosisHepatobiliary disorders | 1/24 |
| Cardiac arrestCardiac disorders | 1/24 |
| Duodenal perforationGastrointestinal disorders | 1/24 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/24 |
| Pulmonary edemaRespiratory, thoracic and mediastinal disorders | 1/24 |
| SepsisInfections and infestations | 1/24 |
| StrokeNervous system disorders | 1/24 |
| Event | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Alanine aminotransferase increasedInvestigations | 20/24 |
| AnemiaBlood and lymphatic system disorders | 20/24 |
| Aspartate aminotransferase increasedInvestigations | 20/24 |
| Blood bilirubin increasedInvestigations | 14/24 |
| HypoalbuminemiaMetabolism and nutrition disorders | 9/24 |
| Alkaline phosphatase increasedInvestigations | 8/24 |
| Abdominal painGastrointestinal disorders | 7/24 |
| FatigueGeneral disorders | 7/24 |
| HypotensionVascular disorders | 6/24 |
| Lymphocyte count decreasedInvestigations | 6/24 |
| Age, Categorical(Participants) | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 20 |
| >=65 years | 4 |
| Age, Continuous(years) | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Median | 51.5 (36 to 71) |
| Sex: Female, Male(Participants) | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Female | 11 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| United States | 24 |
| Prior Chemotherapy(Participants) | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| 5-fluorouracil (5-FU) | 20 |
| Oxaliplatin | 20 |
| Irinotecan | 9 |
| Prior Bevacizumab(Participants) | Hepatic Artery Infusion Pump Chemo With Floxuridine&Dexamethasone in Combination With Systemic Chemo |
|---|---|
| Count of participants | 12 |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Clinical data available during the study and indefinitely.
Access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI).
Ran from Jun 2019 to primary completion in Nov 2025, 76 months.
Results were first posted in Aug 2026, 9 months after primary completion.
Of 498 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 75. This study's 76 months is above that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Floxuridine · Dexamethasone
National Cancer Institute (NCI) →